These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 32627178)

  • 21. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
    Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
    Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lead generation from N-[benzyl(4-phenylbutyl)carbamoyl]amino acid as a novel LPA
    Kobayashi Y; Uneuchi F; Naruse T; Matsuda D; Okumura-Kitajima L; Kajiyama H; Wada R; Yonemoto Y; Nakano K; Toki H; Kamigaso S; Yamagishi J; Tokura S; Kakinuma H; Kuroda S
    Eur J Med Chem; 2023 Nov; 260():115749. PubMed ID: 37639822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogens Counteract the Profibrotic Effects of TGF-β and their Inhibition Exacerbates Experimental Dermal Fibrosis.
    Avouac J; Pezet S; Gonzalez V; Baudoin L; Cauvet A; Ruiz B; Boleto G; Brandely ML; Elmerich M; Allanore Y
    J Invest Dermatol; 2020 Mar; 140(3):593-601.e7. PubMed ID: 31476316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway.
    Bergmann C; Akhmetshina A; Dees C; Palumbo K; Zerr P; Beyer C; Zwerina J; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2011 Dec; 70(12):2191-8. PubMed ID: 21873331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.
    Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M
    Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promotion of Myofibroblast Differentiation and Tissue Fibrosis by the Leukotriene B
    Liang M; Lv J; Jiang Z; He H; Chen C; Xiong Y; Zhu X; Xue Y; Yu Y; Yang S; Wang L; Li W; Guan M; Wan W; He R; Zou H
    Arthritis Rheumatol; 2020 Jun; 72(6):1013-1025. PubMed ID: 31872544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis.
    Zhang Y; Dees C; Beyer C; Lin NY; Distler A; Zerr P; Palumbo K; Susok L; Kreuter A; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2015 May; 74(5):936-43. PubMed ID: 24431397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Knockout of endothelin type B receptor signaling attenuates bleomycin-induced skin sclerosis in mice.
    Akashi K; Saegusa J; Sendo S; Nishimura K; Okano T; Yagi K; Yanagisawa M; Emoto N; Morinobu A
    Arthritis Res Ther; 2016 May; 18(1):113. PubMed ID: 27209208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis.
    Horn A; Palumbo K; Cordazzo C; Dees C; Akhmetshina A; Tomcik M; Zerr P; Avouac J; Gusinde J; Zwerina J; Roudaut H; Traiffort E; Ruat M; Distler O; Schett G; Distler JH
    Arthritis Rheum; 2012 Aug; 64(8):2724-33. PubMed ID: 22354771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX
    Luong VH; Utsunomiya A; Chino T; Doanh LH; Matsushita T; Obara T; Kuboi Y; Ishii N; Machinaga A; Ogasawara H; Ikeda W; Kawano T; Imai T; Oyama N; Hasegawa M
    Arthritis Rheumatol; 2019 Nov; 71(11):1923-1934. PubMed ID: 31173491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis.
    Reich N; Tomcik M; Zerr P; Lang V; Dees C; Avouac J; Palumbo K; Horn A; Akhmetshina A; Beyer C; Xie W; Bennett BL; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2012 May; 71(5):737-45. PubMed ID: 22258492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis.
    Zhang Y; Zhu H; Layritz F; Luo H; Wohlfahrt T; Chen CW; Soare A; Bergmann C; Ramming A; Groeber F; Reuter C; Fornasini G; Soukhareva N; Schreiber B; Ramamurthy S; Amann K; Schett G; Distler JHW
    Arthritis Rheumatol; 2020 Aug; 72(8):1385-1395. PubMed ID: 32182396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts.
    Qian Y; Hamilton M; Sidduri A; Gabriel S; Ren Y; Peng R; Kondru R; Narayanan A; Truitt T; Hamid R; Chen Y; Zhang L; Fretland AJ; Sanchez RA; Chang KC; Lucas M; Schoenfeld RC; Laine D; Fuentes ME; Stevenson CS; Budd DC
    J Med Chem; 2012 Sep; 55(17):7920-39. PubMed ID: 22894757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Dermal Fibrosis in Murine Models of Systemic Sclerosis.
    Yamamoto A; Saito T; Hosoya T; Kawahata K; Asano Y; Sato S; Mizoguchi F; Yasuda S; Kohsaka H
    Arthritis Rheumatol; 2022 May; 74(5):860-870. PubMed ID: 34882985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Antifibrotic Effect of α2AP Neutralization in Systemic Sclerosis Dermal Fibroblasts and Mouse Models of Systemic Sclerosis.
    Kanno Y; Shu E; Kanoh H; Seishima M
    J Invest Dermatol; 2016 Apr; 136(4):762-769. PubMed ID: 26743600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Function-Blocking RHAMM Peptides Attenuate Fibrosis and Promote Antifibrotic Adipokines in a Bleomycin-Induced Murine Model of Systemic Sclerosis.
    Wu KY; Kim S; Liu VM; Sabino A; Minkhorst K; Yazdani A; Turley EA
    J Invest Dermatol; 2021 Jun; 141(6):1482-1492.e4. PubMed ID: 33242499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
    Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
    Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antifibrotic effects of 2-carba cyclic phosphatidic acid (2ccPA) in systemic sclerosis: contribution to the novel treatment.
    Higuchi T; Takagi K; Tochimoto A; Ichimura Y; Norose T; Katsumata Y; Masuda I; Yamanaka H; Morohoshi T; Kawaguchi Y
    Arthritis Res Ther; 2019 Apr; 21(1):103. PubMed ID: 30999934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
    Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T
    Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis.
    Zhang Y; Pötter S; Chen CW; Liang R; Gelse K; Ludolph I; Horch RE; Distler O; Schett G; Distler JHW; Dees C
    Ann Rheum Dis; 2018 May; 77(5):744-751. PubMed ID: 29431122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.